Evidence map›Paper›PMID 36545307›Full record

ReviewFrontiers in pharmacology2022

Using

Minghui Xiu, Yixuan Wang, Dan Yang, Xueyan Zhang, Yuting Dai, Yongqi Liu, Xingyao Lin, Botong Li, Jianzheng He

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Biology · 2026
    Review
  2. Review
  3. Article
  4. The "yeast-drop" treatment protocol in theFrontiers in tuberculosis · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Network analysis andFrontiers in pharmacology · 2025
    Article
  11. Article
  12. Article
  13. International journal of molecular sciences · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Frontiers in microbiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Minghui XiuCollege of Public Health, Gansu University of Chinese Medicine, Lanzhou, China.
Yixuan WangCollege of Public Health, Gansu University of Chinese Medicine, Lanzhou, China.
Dan YangCollege of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China.
Xueyan ZhangCollege of Public Health, Gansu University of Chinese Medicine, Lanzhou, China.
Yuting DaiCollege of Public Health, Gansu University of Chinese Medicine, Lanzhou, China.
Yongqi LiuProvincial-level Key Laboratory for Molecular Medicine of Major Diseases and the Prevention and Treatment with Traditional Chinese Medicine Research in Gansu Colleges and University, Gansu University of Chinese Medicine, Lanzhou, China.
Xingyao LinKey Laboratory of Dunhuang Medicine, Ministry of Education, Lanzhou, China.
Botong LiCollege of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China.
Jianzheng HeProvincial-level Key Laboratory for Molecular Medicine of Major Diseases and the Prevention and Treatment with Traditional Chinese Medicine Research in Gansu Colleges and University, Gansu University of Chinese Medicine, Lanzhou, China.
Gansu University of Traditional Chinese Medicine · CNMinistry of Education of the People's Republic of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic and life-treating inflammatory disease that can occur in multiple parts of the human intestine and has become a worldwide problem with a continually increasing incidence. Because of its mild early symptoms, most of them will not attract people's attention and may cause more serious consequences. There is an urgent need for new therapeutics to prevent disease progression. Natural products have a variety of active ingredients, diverse biological activities, and low toxicity or side effects, which are the new options for preventing and treating the intestinal inflammatory diseases. Because of multiple genetic models, less ethical concerns, conserved signaling pathways with mammals, and low maintenance costs, the fruit fly

Indexed as

Drosophila melanogasterdrug discoveryinflammatory bowel diseasemolecular pathwaysnatural products

Identifiers

PMID36545307
PMCPMC9760693
OpenAlexW4310672669

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.